A study to find out how safe is it to give people a new medicine for asthma (GDC-4379), and to see how this medicine is processed in the body

Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled GDC-4379 conducted in three parts: A single-ascending dose study in healthy volunteers, a multiple-ascending dose study in healthy volunteers, and a proof-of-activity study in patients with mild asthma

  • Healthy Volunteers
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Country
  • New Zealand
Trial Identifier:

GA41024

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      Healthy volunteers for Parts A (n=48) and B (n=32), and asthma patients for Part C (n=48) were enrolled at two study sites in New Zealand to evaluate the safety and tolerability of GDC-4379, an inhibitor of JAK1. Part A was a single-ascending dose study (1–80 mg of GDC-4379). Parts B was a multiple-ascending dose study (3–80 mg QD). Part C was a proof of activity study (10–80 mg QD). Results showed GDC-0214 to be similarly tolerated in active and placebo dose groups. There were no deaths or serious side effects. One participant (Part B) stopped treatment due to a side effect. GDC-4379 showed some activity in reducing inflammation in patients with asthma. Based on this study, researchers decided not to develop GDC-4379 any further because the results showed that patients will need a very high dose of this medicine to control asthma.

      GA41024 Trial Identifier
      All Gender
      18 to 65 Years Age
      Yes Healthy Volunteers

      This clinical trial was done to study a new medicine called, “GDC-4379”, for the treatment of asthma. This study investigated whether it was safe to give people single and multiple doses of GDC-4379. Researchers also wanted to find out what happened to GDC-4379 in the body, and if there was any indication that GDC-4379 may be useful in patients with asthma. One hundred and twenty-eight healthy people and patients with asthma took part in this study at two study centers in one country.

      Trial Summary

      Healthy volunteers for Parts A (n=48) and B (n=32), and asthma patients for Part C (n=48) were enrolled at two study sites in New Zealand to evaluate the safety and tolerability of GDC-4379, an inhibitor of JAK1. Part A was a single-ascending dose study (1–80 mg of GDC-4379). Parts B was a multiple-ascending dose study (3–80 mg QD). Part C was a proof of activity study (10–80 mg QD). Results showed GDC-0214 to be similarly tolerated in active and placebo dose groups. There were no deaths or serious side effects. One participant (Part B) stopped treatment due to a side effect. GDC-4379 showed some activity in reducing inflammation in patients with asthma. Based on this study, researchers decided not to develop GDC-4379 any further because the results showed that patients will need a very high dose of this medicine to control asthma.

      GA41024 Trial Identifier
      GDC-4379 Treatments
      None for healthy volunteers Condition
      Official Title

      Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of inhaled GDC-4379 conducted in three parts: A single-ascending dose study in healthy volunteers, a multiple-ascending dose study in healthy volunteers, and a proof-of-activity study in patients with mild asthma

      Eligibility criteria

      All Gender
      18 to 65 Years Age
      Yes Healthy Volunteers

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now